Creative Planning
ATNM icon

Creative Planning’s Actinium Pharmaceuticals ATNM Stock Holding History

Creative Planning’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-131
Closed -$5K – 2012
2017
Q2 		$5K Buy
131
+50
+62% +$2.09K ﹤0.01% 3963
2017
Q1 		$4K Buy
81
+54
+200% +$2.07K ﹤0.01% 4028
2016
Q4 		$1K Buy
+27
New +$845 ﹤0.01% 4394
2015
Q2 		– Sell
-27
Closed -$2K – 1230
2015
Q1 		$2K Hold
27
– – ﹤0.01% 3844
2014
Q4 		$5K Buy
+27
New +$5.13K ﹤0.01% 3469

Other funds holding ATNM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning's ATNM Position: Q3 2017 in Review

Creative Planning sold out of Actinium Pharmaceuticals (ATNM) in Q3 2017, closing a stake of 131 shares — an estimated $5K sold.

Creative Planning first reported a position in ATNM in Q4 2014 and held it in 5 quarters. The position peaked at $5K in Q2 2017. 31 funds tracked by Wall St. Rank hold ATNM as of Q3 2017.

  • Creative Planning reported no remaining Actinium Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 131 Actinium Pharmaceuticals shares in Q3 2017, an estimated $5K.
  • Creative Planning first reported a position in Actinium Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Creative Planning's Actinium Pharmaceuticals position peaked at $5K in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.